Events

5 Horizons Ventures and Biointelect have announced a strategic partnership and investment alliance designed to help promising biotech and medtech ventures navigate one of the most challenging phases of development.

The trial, spanning multiple centres across the US, is evaluating the performance of RAD 101 in patients with confirmed recurrent brain metastases from a range of solid tumours.

Noxopharm has appointed Dr Olivier Laczka as its new Chief Executive Officer with immediate effect, marking a leadership transition as the clinical-stage company positions itself to capitalise on emerging opportunities in its pipeline.

The therapy is being developed to address the underlying cause of Autosomal Dominant Optic Atrophy, a condition that leads to progressive vision loss and currently has no approved treatment options.

The decision opens the door to approximately 51 military hospitals and 170 VA medical centres, dramatically expanding the company’s reach in the United States and positioning it within systems that routinely handle some of the most challenging trauma cases.

The company has named Chisako Mizutani as Country Manager for Japan, bringing more than two decades of experience in clinical research and leadership in contract research organisations.

The Melbourne-based company confirmed the successful completion of its entitlement offer, drawing strong backing from both existing shareholders and new investors eager to support the next phase of its work.

Entropy Neurodynamics has taken another step forward in its clinical exploration of psychedelic-assisted therapy, announcing that the third patient in its trial of TRP-8803 has completed dosing and achieved what the company describes as a full and controlled psychedelic response.

Clarity Pharmaceuticals (ASX:CU6) has taken another step toward the commercialisation of its prostate cancer imaging agent, signing a manufacturing agreement that significantly broadens its production capacity and geographic reach.

Argent BioPharma has completed the acquisition of AusCann Group Holdings' interest in CannPal Animal Therapeutics, marking an important step in strengthening its neurological pipeline and expanding its reach into veterinary medicine.

Cartherics and Catalent have strengthened their collaboration to accelerate the development and future commercialisation of advanced immune cell therapies.

Australian nuclear medicine company Telix Pharmaceuticals has announced a collaboration with Regeneron to develop new targeted cancer treatments.